scPharmaceuticals Competitors and Similar CompaniesClear all
scPharmaceuticals's competitors and similar companies include Momenta Pharmaceuticals, Oxurion, Sorrento Therapeutics and Merus.
 scPharmaceuticals scPharmaceuticals, a biopharmaceutical company, develops a portfolio of transformative pharmaceutical products for subcutaneous delivery. |  Momenta Pharmaceuticals Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules. |  Oxurion Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. |  Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
|  Merus Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. | |
Founding Date | Founding Date 2014 | Founding Date 2001 | Founding Date 1991 | Founding Date 2006 | Founding Date 2003 |
Type | Type Public | Type Subsidiary | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Burlington, US HQ | Locations Cambridge, US HQ Dublin, IE Cambridge, US | Locations Leuven, BE HQ Dublin 8, IE | Locations San Diego, US HQ San Diego, US | Locations Utrecht, NL HQ Cambridge, US |
Employees | Employees 96256% increase | Employees 76 | Employees 785% increase | Employees 31019% decrease | Employees 260 |
Valuation ($) | Valuation ($) 221.6 m | Valuation ($) N/A | Valuation ($) 626.1 k | Valuation ($) 1.5 m | Valuation ($) 3.6 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $36.3m (FY, 2024) | Revenue (est.) $23.9m (FY, 2019) | Revenue (est.) €555k (FY, 2025) | Revenue (est.) $62.8m (FY, 2022) | Revenue (est.) $36.1m (FY, 2024) |
Cost of goods | Cost of goods $11.4m (FY, 2024) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $25m (FY, 2024) | Gross profit N/A | Gross profit €937k (FY, 2025) | Gross profit N/A | Gross profit $36.1m (FY, 2024) |
Net income | Net income ($85.1m) (FY, 2024) | Net income ($290.1m) (FY, 2019) | Net income (€3.7m) (FY, 2025) | Net income ($577.8m) (FY, 2022) | Net income ($215.3m) (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised $ 62.5m | Total funding raised N/A | Total funding raised $ 3.9m | Total funding raised $ 42.6m | Total funding raised $ 149.3m |
For sources of this data, please see the company profile
View Company Profiles
Momenta Pharmaceuticals
HQ
Cambridge, US
Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules.
View companyOxurion
HQ
Leuven, BE
Employees
78↑ 5% increase
Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye.
View companySorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View companyMerus
HQ
Utrecht, NL
Employees
260
Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients.
View company